Related references
Note: Only part of the references are listed.Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials
Paul Guedeney et al.
EUROPEAN HEART JOURNAL (2022)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Use of PCSK9 Inhibitor in a Mexican Boy with Compound Heterozygous Familial Hypercholesterolemia: A Case Report
Jose Juan Ceballos-Macias et al.
JOURNAL OF THE ENDOCRINE SOCIETY (2020)
PCSK9 inhibition in the management of familial hypercholesterolemia
Masatsune Ogura
JOURNAL OF CARDIOLOGY (2018)
Proprotein convertase subtilisin/kexin 9 inhibition in patients with familial hypercholesterolemia: Initial clinical experience
Annette M. H. Galema-Boers et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2017)
PCSK9 Inhibitors Economics and Policy
Mark A. Hlatky et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice
Kathleen A. Fairman et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2017)
Familial hypercholesterolaemia
Joep C. Defesche et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives
Alejandro Arrieta et al.
PLOS ONE (2017)
Knowing the Prevalence of Familial Hypercholesterolemia Matters
Anne C. Goldberg et al.
CIRCULATION (2016)
Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease
Dhruv S. Kazi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
Erik S. Stroes et al.
EUROPEAN HEART JOURNAL (2015)
Efficiency and Safety of Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody on Hypercholesterolemia: A Meta-Analysis of 20 Randomized Controlled Trials
Chuanwei Li et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2015)
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2013)
Share Paper
